Quebec City, QC, Canada
Medicago is initiating a $1.5 million expansion of its Quebec City manufacturing facility to support avian flu vaccine production for clinical trials. The 2,500-sf addition will include purification, storage, and cGMP vaccine manufacturing space. Construction will begin in January 2009 and reach completion by year-end 2009. Medicago’s existing building, housing 10,000-sf of BSL-2 space and 3,000-sf of cGMP manufacturing space, will begin production of an H5N1 vaccine for Phase 1 clinical trials in 2009. The new addition will house Phase 2 clinical studies.
